UK markets open in 3 hours 15 minutes
  • NIKKEI 225

    27,113.13
    -475.24 (-1.72%)
     
  • HANG SENG

    24,656.46
    0.00 (0.00%)
     
  • CRUDE OIL

    83.64
    +0.33 (+0.40%)
     
  • GOLD FUTURES

    1,842.50
    +0.80 (+0.04%)
     
  • DOW

    34,364.50
    +99.13 (+0.29%)
     
  • BTC-GBP

    26,805.58
    -7.15 (-0.03%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • ^IXIC

    13,855.13
    +86.21 (+0.63%)
     
  • ^FTAS

    4,099.16
    -118.15 (-2.80%)
     

Global Pharma and Biotech Discovery Stage Partnering Report 2021: Deal Trends in Discovery Stage Dealmaking in the Biopharma Industry Since 2014

·6-min read

Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021" report has been added to ResearchAndMarkets.com's offering.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report provides comprehensive access to available deals and contract documents for over 3,900 discovery stage deals.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2014 including financial terms where available including over 3,900 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Report scope

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 include:

  • Trends in discovery stage dealmaking in the biopharma industry since 2014

  • Analysis of discovery stage deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life discovery stage deals

  • Access to over 3,900 discovery stage deals

  • The leading discovery stage deals by value since 2014

  • Most active discovery stage dealmakers since 2014

  • The leading discovery stage partnering 2014

In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021, the available contracts are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal type

  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?
2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte - Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier - GeNeuro
3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer - Spark Therapeutics
3.6.1.b. Case study : Contrafect - Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon - Boehringer Ingelheim - Macrogenics
3.7.1.b. Case study: Fibrocell Science - Intrexon

Chapter 4 - Discovery stage partnering payment strategies
4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making
5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1. Attributes of discovery deals
5.3. Discovery stage partnering by deal type
5.4. Discovery stage partnering by disease type
5.5. Partnering by discovery stage technology type
5.6. Discovery stage partnering by most active company since 2014

Chapter 6 - Payment terms for discovery stage partnering
6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
6.4.2. Discovery stage deal upfront payments
6.4.3. Discovery stage deal milestone payments
6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals
7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers
8.1. Introduction
8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory
9.1. Introduction
9.2. Discovery stage deals with contracts 2014 to 2020

Chapter 10 - Discovery stage deal making by development stage
10.1. Introduction
10.2. Deals by discovery stage

Appendices
Appendix 1 - Discovery stage dealmaking by companies A-Z
Appendix 2 - Discovery stage dealmaking by industry sector
Appendix 3 - Discovery stage dealmaking by stage of development
Appendix 4 - Discovery stage dealmaking by therapy area
Appendix 5 - Discovery stage dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/y18i6z

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting